The filing is a routine update of the corporate deck, no new material catalyst. Monitor upcoming TILVANCE-301 interim ORR analysis and IOV-LUN-202 registrational data for NSCLC, which could be significant catalysts. Quarterly revenue growth trajectory supports the commercial thesis but is already priced into the analyst consensus (80% bullish).
Drugs in focus
IOVA drug pipeline →Amtagvi
● Neutral Named in this 8-K- Impact
- Phase
- Approved (accelerated approval)
- Time to market
- Already approved and marketed (FDA accelerated approval Feb 16, 2024). Confirmatory Phase 3 (TILVANCE-301) is ongoing to convert to full approval.
- Next catalyst
- BLA filing · 2027
What to watchWatch for TILVANCE-301 Phase 3 interim or topline results (undated but the key catalyst for converting accelerated to full approval and expanding into frontline) and quarterly revenue growth trajectory, Q2 2026 guidance is $86M-$88M. Also monitor IOV-LUN-202 NSCLC registrational data (Fast Track, potential launch 2H27). At ~$3.97 with a mean analyst target of $8.80 (177% upside), the stock prices in meaningful commercial execution but not a TILVANCE-301 success.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 7 $6.34entry
- T+1 · 3mo ago +0.95%α +0.98% · $6.40
- T+5 · 3mo ago +10.09%α +9.70% · $6.98
- T+20 · 2mo ago +38.64%α +39.04% · $8.79
- T+60 · 15d ago +25.00%α +27.13% · $7.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Iovance Biotherapeutics filed an 8-K with an updated corporate presentation used at healthcare conferences. The presentation highlights ~66% YoY revenue growth in Q2 2026, a ~$99M quarterly revenue >10% above guidance, ~56% gross margin from cost of sales, and ~$304M cash runway into 2H 2028. The filing is a routine business update with no material new events beyond the existing pipeline and commercial progress.
Key Facts
- 2Q26 revenue ~$99M, >10% above guidance, ~66% YoY growth
- Cash position ~$304M as of June 30, 2026, runway into 2H 2028
- ~56% gross margin from cost of sales in 2Q26, 50% YTD
- >95 authorized treatment centers in North America
- ~2,000 patients treated with commercial and clinical Iovance TIL products
- Lifileucel potential launch in 2L mNSCLC in 2H 2027 with FDA Fast Track Designation
- Phase 3 TILVANCE-301 trial for frontline advanced melanoma enrolling on track
- Phase 2 SARATOGA registrational trial for soft tissue sarcomas commenced in 2Q 2026
Financial Impact
No new material financial information beyond previously disclosed Q2 2026 revenue ~$99M and cash position ~$304M
Risk Factors
- Clinical trial results may not support regulatory approvals
- Commercial adoption of Amtagvi may not sustain current growth rates
- Cash runway only into 2H 2028, may require future capital raises
- Competition from other cell therapies or immunotherapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-092145 |
| Document: tm2622463d1_8k.htm | 0001104659-26-092145 |
| Document: 0001104659-26-092145-index-headers.html | 0001104659-26-092145 |
| Document: 0001104659-26-092145-index.html | 0001104659-26-092145 |
| Document: 0001104659-26-092145.txt | 0001104659-26-092145 |
Track record
21 reports on IOVA
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
- Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
- Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers